Researchers identify first molecular steps that lead to pancreatic cancer
Date: Nov-10-2014 By identifying the molecular starting point when certain cells
in the pancreas become pre-cancerous lesions, researchers behind a new
study believe they have opened the door to exploring ways to prevent
the deadly disease.
Study leader Dr. Peter Storz, a cancer biologist at the Mayo Clinic
in Jacksonville, FL, who - with colleagues - describes the findings in the
journal Cancer Discovery, says:
"Pancreatic cancer develops from these lesions, so if we understand
how these lesions come about, we may be able to stop the cancer train
altogether."
Pressing need for new treatments and ways to prevent pancreatic
cancer
Cancer of the pancreas is one of the most aggressive human cancers and is the fourth leading cause of cancer death in the US.
Dr. Storz says there is a pressing need for new treatments and ways
to prevent pancreatic cancer, one of the most aggressive human cancers.
The disease is the fourth leading cause of cancer death in the US.
On average, patients with pancreatic cancer face a 20% chance of
living more than 1 year after diagnosis. The main reason for such a
poor prospect is that symptoms do not show until the cancer is well
advanced.
According to the National Cancer Institute, in 2014, over
46,400 people will be diagnosed with pancreatic cancer and over
39,500 will die of the disease.
For the study, the team investigated cells containing mutations of a gene that regulates a cell division protein. Called Kras, the gene is known to be mutated in over 95% of pancreatic cancer cases.
Study details steps that mutated cells follow as they transform
into pre-cancerous lesions
The researchers describe how they identified the detailed steps that
Kras-mutated acinar cells follow as they change into duct-like cells
with properties similar to stem cells - a type of cell often found in
cancer.
They noticed that Kras proteins in the acinar cells switched on a
molecule called ICAM-1. This in turn attracts macrophages -
inflammatory immune cells that release a variety of proteins, including
some that loosen the pancreatic cell structures. When they become
looser, the acinar cells then transform into different types of cell -
including the type that leads to pre-cancerous lesions.
Dr. Storz says their study shows a "direct link between Kras
mutations and the inflammatory environment that drive the initiation of
pancreatic cancer."
Team found two ways to stop process toward pre-cancerous lesions in
mice
The team also found they could halt the process in mice. They did
this in two ways. One way was by depleting the macrophages, and the
other way was by blocking the transforming cells with an antibody that shuts
down ICAM-1.
"Doing either one reduced the number of precancerous lesions," says
Dr. Storz, noting that an antibody that blocks ICAM-1 has already been
developed and is currently being tested for treating stroke, rheumatoid
arthritis, and other ailments.
He also says the key to developing targeted ways to prevent and
treat pancreatic cancer will be understanding "the crosstalk between
acinar cells with Kras mutations and the microenvironment of those
cells."
The National Institutes of Health funded the research.
The study follows another recent report from Medical News
Today about the prospect of a
simple blood test for pancreatic cancer, as more potential
biomarkers for the disease emerge.
Written by Catharine Paddock PhD
Not to be reproduced without permission.
Follow @twitter
window.twttr = (function (d, s, id) {
var t, js, fjs = d.getElementsByTagName(s)[0];
if (d.getElementById(id)) return;
js = d.createElement(s); js.id = id;
js.src= "https://platform.twitter.com/widgets.js";
fjs.parentNode.insertBefore(js, fjs);
return window.twttr || (t = { _e: [], ready: function (f) { t._e.push(f) }
}(document, "script", "twitter-wjs"));
Courtesy: Medical News Today
Note: Any medical information available in this news section is not intended as a substitute for informed medical
advice and you should not take any action before consulting with a health care professional.